Enhancing Benefit With Durvalumab in NSCLC After the PACIFIC Trial
Andreas Rimner, MD, gives an overview of his presentation titled, “Crossing the PACIFIC,” which he presented at the 2019 New York Lung Cancers Symposium. He evaluates some potential next steps for durvalumab (Imfinzi) following the practice-changing results from the PACIFIC trial.
Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center, gives an overview of his presentation titled, “Crossing the PACIFIC,” which he presented at the 2019 New York Lung Cancers Symposium. He evaluates some potential next steps for durvalumab (Imfinzi) following the practice-changing results from the PACIFIC trial.
The PACIFIC trial evaluated durvalumab following concurrent chemoradiation in patients with stage III unresectable nonsmall cell lung cancer. Due to the magnitude of benefit observed in this study, the standard of care for this patient population was changed.
There is now a question of how to move forward in prolonging progression-free survival and overall survival after the PACIFIC trial. Rimner says several ideas include giving durvalumab even earlier, combining durvalumab with other drugs to enhance the effects, and giving durvalumab to patients who are not fit for the classic PACIFIC regimen. There is also a question of whether durvalumab can be given to surgical candidates.
TMLI Trial Shows Potential in Relapsed/Refractory Leukemia
October 2nd 2024In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow and lymphoid irradiation with cyclophosphamide and etoposide in high-risk acute leukemia.
Read More
SABR and Hypofractionated Chemoradiation Improves Lung Cancer Outcomes
September 30th 2024Percy Lee, MD, discussed findings from a trial evaluating a hypofractionated approach to concurrent chemoradiation, incorporating an adaptive stereotactic ablative radiotherapy boost in non–small cell lung cancer.
Read More
